First quarter 2026 results for Aker BioMarine

Highlights first quarter 2026: • Q1 revenues reached USD 57.3 million, an increase of 13% year-over-year (YoY), with adjusted EBITDA of USD 12.5 million, up 34% from the prior year. • Human Health Ingredients delivered USD 31.8 million in revenue, up 22% YoY. Krill oil revenues reached an all-time-high of USD 29.3 million, up 26% YoY. Adjusted EBITDA increased 27% to USD 14.9 million. • Consumer Health Products generated USD 28.1 million in revenue, down 2% YoY. Adjusted EBITDA of USD 1.8 million, with margin up YoY on lower SG&A. From Q1 2026, the segment includes both Lang and Epion/Kori • Refinanced NOK 1,600 million bond with a new USD 175 million term loan • Emerging Business no longer reported as a separate segment

“The first quarter marks an all-time-high for Superba krill oil sales, reflecting strong underlying demand across our customer base. Krill oil revenues grew 26% year-over-year, supported by both higher volumes and improved price mix. We have now delivered three consecutive years of year-over-year growth in quarterly krill oil revenues”, said Matts Johansen, CEO of Aker BioMarine.

Segment performance Human Health Ingredients grew revenues by 22% year-over-year, with krill oil revenues up 26% to USD 29.3 million – an all-time-high quarter for Superba. Growth was driven mainly by higher volumes, with additional support from an improved price mix reflecting a higher capsule share. Gross margin came in slightly below last year due to product mix, while EBITDA margin improved as SG&A growth remained modest.

Consumer Health Products reported revenues of USD 28.1 million, down 2% year-over-year. From the first quarter of 2026, the segment includes both Lang and Epion/Kori, with internal sales and profit eliminated. Lang grew modestly across most categories, while Epion is in an ongoing marketing repositioning that is weighing on short-term revenues but is expected to be positive over time. Gross margin was on par with last year, while EBITDA margin improved on lower SG&A.

Outlook The Human Health Ingredients segment sees continued year-over-year growth, supported by good underlying demand across multiple markets. In Consumer Health Products, revenues are expected to return to modest growth. The Understory sales process is still ongoing with advanced discussions with one interested party. Following recent interest in the Human Health Ingredient business unit, the Company has engaged Jefferies and Houlihan Lokey as investment banks to support the Company in exploring alternatives and work towards a transaction in 2026.

Attached is the quarterly presentation and report for Q1. Group reported financial figures can be downloaded in an excel from the company’s investor page: Investor - Analyst information

At 08:30 CET today, the management hosts a webcast. The webcasted presentation will be in English. To join, please use the link that is available at www.akerbiomarine.com/investor.

A replay of the presentation will be made available soon after the presentation at the same web address.

For further information, please contact Christopher Robin Vinter, SVP Finance Mobile: +47 911 60 820 Email: Christopher.vinter@akerbiomarine.com

This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act.

About Aker BioMarine Aker BioMarine is a leading human health and nutrition innovator that develops krill-derived products for consumer health and nutrition. Krill is a natural, powerful, and health-promoting source of nutrients from the pristine waters of Antarctica, and Aker BioMarine has a unique position in its industry. The ingredient portfolio consists of Superba Krill Oil, Lysoveta, Revervia, and PL+, as well as the consumer brand, Kori Krill. The innovative approach also extends into the spin-offs AION (reduce and recycle plastic waste across industries) and Understory (a protein brand). Aker BioMarine is listed on the Oslo Stock Exchange (AKBM). More information is available at www.akerbiomarine.com.